EVH - Evolent Health, Inc.

NYSE - NYSE 延遲價格。貨幣為 USD。
-0.19 (-0.60%)
收市:04:00PM EDT
31.46 -0.04 (-0.13%)
收市後: 04:27PM EDT
買盤31.53 x 900
賣出價31.55 x 900
今日波幅31.50 - 32.01
52 週波幅21.83 - 39.78
Beta 值 (5 年,每月)1.55
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-0.38
業績公佈日2023年7月31日 - 2023年8月04日
遠期股息及收益率無 (無)
1 年預測目標價47.25
  • Benzinga

    Evolent Health Q4 Top-Line Beats Expectation, Analyst Points To Visible Growth Outlook

    Evolent Health Inc (NYSE: EVH) reported Q4 adjusted EPS of $0.10, missing the consensus of $0.16, compared to $0.08 a year ago. Revenues increased 54% Y/Y to $382.43 million, beating the consensus of $372.93 million. Total Lives on the Platform of 20.6 million as of Dec. 31, 2022, compared to 17.7 million a year ago. Total cases managed during the quarter within surgical management and advanced care planning totaled 15.7k, yielding an average per case revenue of $2.8k. Guidance: Evolent Health s

  • Insider Monkey

    Here’s Why Evolent Health (EVH) Declined in Q4

    Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. Small-cap stocks posted solid returns in the fourth quarter for the first time in 2022. The Russell 2000 Growth Index was up 4.11% trailing the Russell 2000 […]

  • Benzinga

    This Analyst Is Bullish On Evolent Health's Recent Deal, Calls 'Highly Strategic Acquisition'

    Thursday after close, Evolent Health Inc (NYSE: EVH) agreed to acquire Magellan Specialty Health, the specialty benefit management organization owned by Centene Corporation (NYSE: CNC), for $650 million at the close plus additional contingent consideration of up to $150 million based on 2023 performance. William Blair is positive on the acquisition and believes this is consistent with management's prior commentary that Evolent would consider strategic assets that fit under the specialty care man

  • Benzinga

    Centene Agrees To Divest Magellan Specialty Health To Evolent Health

    Evolent Health Inc (NYSE: EVH) has agreed to acquire NIA (also known as Magellan Specialty Health), the specialty benefit management organization owned by Centene Corporation (NYSE: CNC). The organization focuses on managing cost and quality in radiology, musculoskeletal, physical medicine, and genetics. Deal consideration includes $650 million at the close plus additional contingent consideration of up to $150 million based on 2023 performance. The upfront consideration will be partly funded by

  • Insider Monkey

    Ray Dalio Stock Portfolio Q3 2022: Top 10 Small-Cap Stocks

    In this article, we discuss the top 10 small-cap stocks from Ray Dalio’s Q3 2022 portfolio. If you want to see more stocks in this selection, check out Ray Dalio Stock Portfolio Q3 2022: Top 5 Small-Cap Stocks. According to Royce Investment Partners, although equity prices declined in the volatile market environment through the first […]

  • Insider Monkey

    Top 10 Stock Picks of Joe Milano’s Greenhouse Funds

    In this article, we examined Joe Milano’s portfolio management strategy and approach to investing in stocks. We also reviewed the top 10 stock picks of Joe Milano’s Greenhouse Funds. You can skip our detailed discussion about Joe Milano’s investment philosophy and portfolio management strategies and jump directly to the Top 5 Stock Picks of Joe […]

  • Benzinga

    Evolent Expands Its Portfolio For Musculoskeletal Conditions With This Deal

    View more earnings on EVHSee more from BenzingaOyster Point Outlines Restructuring Plan With Savings Of Up To $48M In 202389bio Posts Promising Pegozafermin Data For Severe HypertriglyceridemiaDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.